Drug Type Aptamers |
Synonyms 180-D1-036, NOX-E36 |
Target |
Mechanism CCL2 inhibitors(C-C motif chemokine 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | CZ | 01 Mar 2012 | |
Diabetes Mellitus, Type 2 | Phase 2 | DE | 01 Mar 2012 | |
Diabetes Mellitus, Type 2 | Phase 2 | HU | 01 Mar 2012 | |
Diabetes Mellitus, Type 2 | Phase 2 | PL | 01 Mar 2012 | |
Diabetes Mellitus, Type 2 | Phase 2 | RO | 01 Mar 2012 | |
Proteinuria | Phase 2 | CZ | 01 Mar 2012 | |
Proteinuria | Phase 2 | DE | 01 Mar 2012 | |
Proteinuria | Phase 2 | HU | 01 Mar 2012 | |
Proteinuria | Phase 2 | PL | 01 Mar 2012 | |
Proteinuria | Phase 2 | RO | 01 Mar 2012 |
Phase 1 | Diabetic Nephropathies CCL2 (MCP-1) | - | oukepchdtj(ezgohcevth) = hgsnkcgrun zptjnmhapq (ifnomynped ) View more | Positive | 30 Oct 2012 | ||
Placebo | oukepchdtj(ezgohcevth) = lpewwxdncy zptjnmhapq (ifnomynped ) |